A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma
- Study HIC#:2000032949
- Last Updated:01/18/2023
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
For more information about this study, including how to volunteer, contact:
- Phone Number: 1-203-752-7835
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact firstname.lastname@example.org, or call +18779788343 for more information.
Trial Purpose and Description
Primary Outcome Measures :
- Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Dose Limiting Toxicities (DLTs) [ Time Frame: Up to 54 months ]This will be evaluated by looking at the number of participants with treatment-related adverse events, serious adverse events (SAEs), and dose-limiting toxicities (DLTs), which are medical problems severe enough to stop study doctors from increasing a treatment dose.
- Phase 2: Antitumor Activity Assessed by Overall Response Rate (ORR) Based on 2014 Lugano Classification Using Computerized Tomography (CT) Imaging as the Primary Modality [ Time Frame: Up to 54 months ]
- Participants with expected life expectancy of >12 weeks.
- Participants must have histologically confirmed R/R PTCL (local pathology report) as defined by 2016 World Health Organization (WHO) classification. The following subtypes are eligible for the study:
- Extranodal natural killer (NK)/T-cell lymphoma nasal type.
- Enteropathy-associated T-cell lymphoma.
- Monomorphic epitheliotropic intestinal T-cell lymphoma.
- Hepatosplenic T-cell lymphoma.
- Subcutaneous panniculitis-like T-cell lymphoma.
- Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).
- Angioimmunoblastic T-cell lymphoma.
- Follicular peripheral T-cell lymphoma.
- Nodal peripheral T-cell with T-follicular helper (THF) phenotype.
- Anaplastic large-cell lymphoma (ALCL).
- Participants must have evidence of progressive disease and must have received at least two prior systemic therapies.
- Participants must have measurable disease by contrast-enhanced diagnostic CT (at least 1 nodal lesion >1.5 centimeters (cm) or extranodal lesions >1.0 cm).
- Participants with CD30-positive disease must have received, be ineligible for, or intolerant to brentuximab vedotin.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- Acceptable organ function as per protocol.
- Women of childbearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.
- Prior treatment with tolinapant or any hypomethylating agent.
- Hypersensitivity to tolinapant or oral decitabine/cedazuridine, excipients of the drug product, or other components of the study treatment regimen.
- Poor medical risk because of systemic diseases (e.g., uncontrolled infections) in addition to the qualifying disease under study.
- Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise participant safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of tolinapant.
- A history of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions:
- Abnormal left ventricular ejection fraction.
- Congestive cardiac failure of Grade ≥3.
- Unstable cardiac disease.
- History or presence of complete left bundle branch block, third-degree heart block, cardiac pacemaker, or clinically significant arrhythmia.
- History of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy.
- Screening 12-lead electrocardiogram (ECG) with measurable QTc interval of ≥470 milliseconds (msec) (according to either Fridericia's or Bazett's correction).
- Any other condition that, in the opinion of the investigator, could put the participant at increased cardiac risk.
- Known history of human immunodeficiency virus (HIV) infection; or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.
- Grade 3 or greater neuropathy.
- Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the participant to high risk of noncompliance with the protocol treatment or assessments.
- Prior anticancer treatments or therapies within the indicated time window before first dose of study treatment (tolinapant), as follows:
- Cytotoxic chemotherapy or radiotherapy within 4 weeks prior.
- Monoclonal antibodies within 4 weeks prior.
- At least 12 weeks must have elapsed since chimeric antigen receptor T-cell (CAR-T) infusion.
- Small molecules or biologics (investigational or approved) within the longer of 3 weeks or 5 half-lives before study treatment.
- Monoclonal antibody treatment for rheumatologic conditions within 4 weeks of study drug initiation.
- Concurrent second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy or superficial bladder cancer.
- Any concurrent second malignancy that is metastatic.
- Known central nervous system (CNS) lymphoma.
- Participants with a history of allogeneic transplant are excluded from this study.
- Autotransplant within 100 days of the first dose of the study drug(s).
- Systemic corticosteroids >10 mg prednisone equivalent within 7 days of the first dose of study drug(s).
- Anti-T-cell directed therapy:
- Lymphotoxic agents (e.g., anti-CD52) in the past 12 months.
- Inhibitory drugs (e.g., calcineurin inhibitors) within 4 weeks of the first dose of study drug(s).
- Use of a concomitant medication which is a moderate or strong CYP3A4 inhibitor/inducer within 2 weeks of the start of the study.
- Use of any vaccine within 10 days of the first dose of the study drug(s).